Judah Rajendran

Judah Rajendran

Auto-generated profile, based on publicly available information

Judah Rajendran

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2025 in Structural Heart
Verified
Journal Article
Open access
BBBesir Besir
Besir Besir
SRShivabalan Kathavarayan Ramu
Shivabalan Kathavarayan Ramu
TLTamari Lomaia
Tamari Lomaia
MMMaryam Muhammad Ali Majeed-Saidan
Maryam Muhammad Ali Majeed-Saidan
JRJudah Rajendran
Judah Rajendran
SKSamir R. Kapadia
Samir R. Kapadia
Patients with small annuli are at risk for worse hemodynamic performance after transcatheter aortic valve replacement (TAVR). It is debatable whether a small annulus confers worse outcomes. This study explored the clinical outcomes following TAVR for patients with small and large annuli across flow-gradient subgroups of aortic stenosis (AS). This is a retrospective cohort of patients >18 years who underwent TAVR at Cleveland Clinic between 2016 and 2020. Patients were classified into 2 groups according to annular size: small (area ≤430 mm2) and large (area >430 mm2). Patients undergoing TAVR with self-expanding valves and those with annular sizing using transesophageal echocardiography were excluded. Each group was subclassified into classical low-flow low-gradient (LFLG) AS, paradoxical LFLG AS, normal-flow low-gradient AS, and high-gradient AS. Clinical outcomes included mortality and heart failure rehospitalization. The study included 1866 patients, of which 709 (38%) had small annuli. There was no difference in heart failure rehospitalization and mortality between the groups in any of the 4 flow-gradient patterns: hazard ratio (HR) ​= ​0.93 (95% confidence interval [CI]: 0.51-1.69) for patients with classical LFLG AS, HR ​= ​0.95, CI (0.62-1.47) for patients with paradoxical LFLG AS, HR = ​1.16, CI (0.49-2.74) for patients with normal-flow low-gradient AS, and HR = ​0.73, CI (0.50-1.07) for patients with high-gradient AS, using large annulus as a reference. Patients with small annuli had higher mean gradients, lower dimensionless valve index, and a higher incidence of hypoattenuated leaflet thickening and structural valve deterioration post-TAVR. Patients with small and large annuli have similar intermediate-term clinical outcomes post-TAVR across all flow-gradient patterns treated with balloon-expandable valve.

27 March 2025 in Structural Heart
Verified
Journal Article
Open access
ARAkiva Rosenzveig
Akiva Rosenzveig
SRShivabalan Kathavarayan Ramu
Shivabalan Kathavarayan Ramu
BBBesir Besir
Besir Besir
TLTamari Lomaia
Tamari Lomaia
JRJudah Rajendran
Judah Rajendran
SKSamir R. Kapadia
Samir R. Kapadia
Paravalvular leak (PVL) remains a frequent complication of transcatheter aortic valve replacement (TAVR). The long-term consequences of mild PVL on outcomes have been debated. This study aimed to investigate the clinical and hemodynamic outcomes of mild PVL over a 2-year period. We conducted a retrospective cohort study of 2601 adult patients who underwent TAVR at the Cleveland Clinic between January 2016 and July 2021. Patients were categorized based on postprocedural PVL severity (mild vs. no/trace PVL). Differences in 2-year clinical outcomes, including all-cause mortality and heart failure hospitalizations, were assessed using Cox regression analysis, while hemodynamic changes were analyzed with a linear mixed model. Mild PVL was present in 140 patients (5%). Compared to those with no/trace PVL, these patients were older, had a lower body mass index, higher prevalence of concentric left ventricular hypertrophy, and more frequent significant mitral regurgitation. Hemodynamic parameters, including transvalvular aortic mean gradient, left ventricular ejection fraction, and ventricular dimensions, remained similar between groups at 30 days, 1 year, and 2 years. Multivariate Cox regression showed no significant association between mild PVL and 2-year all-cause mortality (hazard ratio: 1.24, 95% CI: 0.65 to 2.39, p = 0.51) or heart failure hospitalization (hazard ratio: 1.19, 95% CI: 0.53 to 2.66, p = 0.67). Mild PVL after TAVR is not associated with adverse long-term clinical outcomes or significant impairment in cardiac remodeling within the first 2 years postprocedure compared to no/trace PVL.

1 July 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
ARAkiva Rosenzveig
Akiva Rosenzveig
LTLeben Tefera
Leben Tefera
AAAnkit Agrawal
Ankit Agrawal
JRJudah Rajendran
Judah Rajendran
FMFaysal Massad
Faysal Massad
ANAravinda Nanjundappa
Aravinda Nanjundappa
Background: Peripheral artery disease (PAD) affects >236 million people globally, particularly among those with type 2 diabetes. GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1 RAs) offer cardiovascular and kidney benefits, but their impact on PAD‐specific outcomes is underexplored. This study evaluates long‐term GLP‐1 RA effects on adverse outcomes in this population. Methods: A retrospective cohort study using the TriNetX platform (January 1, 2010–January 1, 2025) included patients with both PAD and type 2 diabetes prescribed either GLP‐1 RAs or metformin, excluding those with recent cardiovascular events, end‐stage renal disease, or prior amputations. Propensity score matching was performed to account for confounding. Outcomes at 5 years included mortality, myocardial infarction, hospitalization, stroke, revascularization, amputations, dialysis, major adverse cardiovascular events, and kidney events. Results: After matching, 2133 patients per cohort were analyzed in the overall group with PAD. At 5 years, GLP‐1 RA therapy was associated with lower mortality (10.31% versus 14.49%; hazard ratio [HR], 0.74 [95% CI, 0.62–0.88]; P =0.0005), hospitalization (69.3% versus 74.7%; HR, 0.87 [95% CI, 0.81–0.94]; P =0.0002), revascularization (4.69% versus 7.27%; HR, 0.64 [95% CI, 0.50–0.82]; P =0.0004), major amputation (2.30% versus 4.36%; HR, 0.52 [95% CI, 0.37–0.74]; P =0.0002), and minor amputation (4.03% versus 6.42%; HR, 0.63 [95% CI, 0.48–0.83]; P =0.0007). major adverse cardiovascular events, myocardial infarction, stroke, and major adverse kidney events were similar between groups. Conclusions: GLP‐1 RAs were associated with lower rates of mortality, major amputation, revascularization, and hospitalization in PAD and type 2 diabetes patients. These findings support prioritizing GLP‐1 RAs for limb‐specific and cardiovascular outcomes in this high‐risk group.

1 May 2025 in Vasa
Verified
Journal Article
Closed access
LTLeben Tefera
Leben Tefera
ARAkiva Rosenzveig
Akiva Rosenzveig
JRJudah Rajendran
Judah Rajendran
BRBhairavi Rajasekar
Bhairavi Rajasekar
JKJoseph Kassab
Joseph Kassab
PCPulkit Chaudhury
Pulkit Chaudhury

12 May 2025 in Structural Heart
Verified
Journal Article
Open access
BBBesir Besir
Besir Besir
MMMaryam Muhammad Ali Majeed-Saidan
Maryam Muhammad Ali Majeed-Saidan
SRShivabalan Kathavarayan Ramu
Shivabalan Kathavarayan Ramu
TLTamari Lomaia
Tamari Lomaia
JRJudah Rajendran
Judah Rajendran
SKSamir R. Kapadia
Samir R. Kapadia
Flow is known to typically improve after transcatheter aortic valve replacement (TAVR); however, the characteristics correlating with improvement are still unclear. This study sought to explore the outcomes of patients with low-flow low-gradient aortic stenosis (LFLG AS) and flow improvement following TAVR compared to those without flow improvement, in addition to the predictors of flow improvement. This is a retrospective cohort of patients >18 years of age who underwent TAVR at Cleveland Clinic between 2016 and 2020. Only patients with aortic valve area <1 cm2, aortic valve mean gradient <40 mmHg, and stroke volume index (SVI) ​<35 mL/m2 were included. Patients were classified into 2 groups according to whether SVI improved by 20% or more at the 30-day follow-up. Patients who underwent valve-in-valve TAVR were excluded. Binary logistic regression was used to evaluate the predictors of flow improvement. A total of 633 patients had LFLG AS. Two hundred twenty-eight patients (36%) had SVI improvement by 20% or more. Male sex, left ventricular ejection fraction (LVEF) improvement by 10% or more 30 days post-TAVR, lower baseline SVI and paradoxical LFLG AS predicted flow improvement. There was no difference in mortality and heart failure rehospitalization between patients with and without flow improvement. One-third of patients with LFLG AS show an improvement in flow post-TAVR. Paradoxical LFLG AS, male sex, lower baseline SVI, and improvement in LVEF correlated with flow improvement, whereas baseline LVEF did not. There was no difference in clinical outcomes between patients with and without flow improvement post-TAVR.

2 May 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
JRJudah Rajendran
Judah Rajendran
SRShivabalan Kathavarayan Ramu
Shivabalan Kathavarayan Ramu
AKAkhilesh Khuttan
Akhilesh Khuttan
BBBesir Besir
Besir Besir
TLTamari Lomaia
Tamari Lomaia
SKSamir R. Kapadia
Samir R. Kapadia